Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users
NCT03059563 · University of California, Los Angeles · PHASE1 · terminated · last registry update 2024-05-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Global pandemic” | – | Registry record, University of California, Los Angeles |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CHRNB2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-03Results posted on the registry: Yale University, a drug against CHRNB2 (NCT04180020)
- 2025-02-12Phase 3 first posted: State University of New York at Buffalo, Combination Nicotine Replacement Therapy (patch and lozenge) (NCT06822049)
- 2025-02-11Phase 3 first posted: University of Oklahoma, a drug against CHRNB2 (NCT06820034)
- 2025-02-06Phase 3 first posted: Fred Hutchinson Cancer Center, Nicotine Gum + Nicotine Patch (NCT06811038)
- 2024-09-19Results posted on the registry: VA Office of Research and Development, a drug against CHRNB2 (NCT03655132)
- 2023-09-25Phase 3 first posted: Jasper A. Smits, Nicotine patch (NCT06053567)
- 2023-09-13Phase 3 first posted: Rutgers, The State University of New Jersey, a drug against CHRNB2 (NCT06033599)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision